For evaluation of the impact of TLR7 agonist-mediated repolarization of TAMs and MDSCs on the efficacy of CAR T cell therapies in solid tumors, we required a cancer cell line that would be devoid of both folate receptors and TLR7, so that our FA-TLR7-1A conjugate could neither bind nor directly stimulate the implanted cancer cells. The gene discussed is TLR7; the disease is cancer.